Pnc Financial Services Group, Inc. Myovant Sciences Ltd. Transaction History

Pnc Financial Services Group, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$13.8 - $27.62 $1,380 - $2,762	-100 Reduced 3.85%	2,500 $69,000
Q3 2020 Nov 06, 2020	SELL	$14.05 - $22.6 $857 - $1,378	-61 Reduced 2.29%	2,600 $36,000
Q2 2020 Aug 07, 2020	BUY	$7.34 - $20.84 $18,350 - $52,100	2,500 Added 1552.8%	2,661 $54,000
Q1 2020 May 08, 2020	BUY	$6.55 - $14.76 $399 - $900	61 Added 61.0%	161 $1,000
Q4 2019 Feb 07, 2020	BUY	$4.2 - $19.21 $420 - $1,921	100 New	100 $1,000
Q3 2018 Nov 09, 2018	SELL	$19.33 - $26.78 $33,827 - $46,865	-1,750 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$9.93 - $15.47 $17,377 - $27,072	1,750	1,750 $0

61.3K

Ticker MYOV
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 96,802,800
Description
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain...

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.